Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Central Precocious Puberty (CPP)
Interventions: Leuprolide Acetate (LA); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 17
States / cities: Long Beach, California • San Diego, California • Aurora, Colorado + 14 more

Conditions: Glabellar Lines
Interventions: Placebo, AGN-151586; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Birmingham, Alabama • Encino, California • Los Angeles, California + 15 more

Conditions: Ventral Hernia, Abdominal Hernia
Interventions: BOTOX Dose A, Placebo for BOTOX, BOTOX Dose B, BOTOX Dose C; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Mineola, New York • Charlotte, North Carolina

Conditions: Healthy Volunteers
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida • Grayslake, Illinois

Conditions: Post-Operative Atrial Fibrillation
Interventions: AGN-151607, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Stanford, California • New Haven, Connecticut • Washington D.C., District of Columbia + 16 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty; Drug · Procedure
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 51
States / cities: Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more

Conditions: Psoriasis
Interventions: Risankizumab, Apremilast; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 26
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more

Conditions: Healthy Volunteer
Interventions: ABBV-552; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Pancreatitis
Interventions: CREON; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Stanford, California • Gainesville, Florida • Baltimore, Maryland + 3 more

Conditions: Chronic Plaque Psoriasis
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 222
States / cities: Birmingham, Alabama • Daphne, Alabama • Huntsville, Alabama + 173 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib, Dupilumab, Placebo to dupilumab, Placebo to upadacitinib; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 52
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 43 more

Conditions: Healthy Volunteers
Interventions: Lutikizumab Dose A, Lutikizumab Dose B; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Cypress, California • Grayslake, Illinois • Austin, Texas

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

Chronic Plaque Psoriasis (Ps) Registry

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

About this AbbVie sponsor directory page